Express Scripts (ESRX) Given a $101.00 Price Target by Mizuho Analysts

Mizuho set a $101.00 price target on Express Scripts (NASDAQ:ESRX) in a research note published on Monday. The firm currently has a hold rating on the stock.

Other equities research analysts also recently issued research reports about the company. BidaskClub downgraded Express Scripts from a buy rating to a hold rating in a research report on Tuesday, July 10th. Robert W. Baird downgraded Express Scripts from an outperform rating to a neutral rating and set a $81.00 price target on the stock. in a research report on Friday, July 20th. Royal Bank of Canada raised their price target on Express Scripts to $94.00 and gave the company an outperform rating in a research report on Monday, August 27th. Barclays raised their price target on Express Scripts from $83.00 to $90.00 and gave the company an equal weight rating in a research report on Thursday, November 1st. Finally, William Blair upgraded Express Scripts from a market perform rating to an outperform rating in a research report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Express Scripts has a consensus rating of Hold and a consensus price target of $89.07.

Shares of ESRX stock traded up $0.06 on Monday, reaching $99.54. The company’s stock had a trading volume of 687,653 shares, compared to its average volume of 3,161,721. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.65 and a current ratio of 0.77. Express Scripts has a 12-month low of $59.17 and a 12-month high of $100.43. The company has a market capitalization of $55.37 billion, a PE ratio of 14.02, a price-to-earnings-growth ratio of 1.24 and a beta of 0.89.

Express Scripts (NASDAQ:ESRX) last issued its quarterly earnings data on Wednesday, October 31st. The company reported $2.43 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.01. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. The company had revenue of $25.56 billion for the quarter, compared to the consensus estimate of $25.11 billion. During the same quarter last year, the business posted $2.51 earnings per share. The firm’s revenue was up 3.6% compared to the same quarter last year. On average, sell-side analysts forecast that Express Scripts will post 9.08 EPS for the current fiscal year.

In other news, insider Christine Houston sold 12,898 shares of the firm’s stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the transaction, the insider now directly owns 110,908 shares of the company’s stock, valued at $9,427,180. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.79% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the company. Landaas & Co. WI ADV bought a new position in shares of Express Scripts during the second quarter valued at about $102,000. Kaizen Advisory LLC grew its stake in shares of Express Scripts by 147.6% during the second quarter. Kaizen Advisory LLC now owns 1,342 shares of the company’s stock valued at $104,000 after buying an additional 800 shares during the last quarter. Adviser Investments LLC grew its stake in shares of Express Scripts by 321.9% during the second quarter. Adviser Investments LLC now owns 1,481 shares of the company’s stock valued at $114,000 after buying an additional 1,130 shares during the last quarter. TRUE Private Wealth Advisors bought a new position in shares of Express Scripts during the third quarter valued at about $115,000. Finally, Sun Life Financial INC grew its stake in shares of Express Scripts by 758.8% during the second quarter. Sun Life Financial INC now owns 1,520 shares of the company’s stock valued at $117,000 after buying an additional 1,343 shares during the last quarter. 84.20% of the stock is currently owned by hedge funds and other institutional investors.

Express Scripts Company Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply